Veerhealth Care Limited

Veerhealth Care Limited announced its Q1FY27 unaudited financial results, showcasing significant year-over-year growth. Total revenues surged by 388.13% to ₹25.09 Crore, EBITDA grew by 233.87% to ₹2.07 Crore, and PAT increased by 412.50% to ₹1.23 Crore. The company also highlighted several key orders, including ₹293 Lakhs for body care products from a New York-based company and ₹1824.40 Lakhs for skincare products from an Indian FMCG major. USFDA clearance for OTC products and advanced discussions for exports to Russia were also noted. Veerhealth Care anticipates total income of ₹105 crores with PAT of ₹5-6 crores in FY26-27 and ₹156 crores with PAT of ₹9-10 crores in FY27-28.

Veerhealth Care Ltd announced that its Board of Directors, in a meeting held on August 13, 2026, approved the unaudited financial results for the quarter ended June 30, 2026, along with the Limited Review Report. The Board also approved the Director's Report for the financial year ending March 31, 2026, and decided to convene the 34th Annual General Meeting on September 23, 2026. Additionally, the company accepted the resignation of Ms. Ashita Chittora as Company Secretary and Compliance Officer, effective August 13, 2026, and approved the appointment of Ms. Ruchi Shah to the same positions, also effective August 13, 2026. The company also noted the receipt of ₹487.25 lakh as part consideration for the issue of 1,00,00,000 warrants.

Veerhealth Care Ltd announced that its Board of Directors, in a meeting held on August 13, 2026, approved the unaudited financial results for the quarter ended June 30, 2026. The company also approved the Director's Report for the financial year ending March 31, 2026, and decided to convene the 34th Annual General Meeting on September 23, 2026. Key management changes were also noted, including the resignation of Ms. Asbita Chittora as Company Secretary and Compliance Officer, effective August 13, 2026, and the subsequent appointment of Ms. Ruchi Shah to the same roles, also effective August 13, 2026. The financial results show revenue from operations of ₹2492.56 lakhs for the quarter ended June 30, 2026.

Veerhealth Care Ltd has announced receiving a repeat order worth ₹5.27 Crores for the supply of skincare products from a leading Indian FMCG company. This order is for face care products and is expected to be executed within 45 days. The company also highlighted a recent export order of ₹15.74 lakhs for Gripe Water from Sudan, marking its entry into the African market. Veerhealth Care anticipates a total income of ₹105 crores with a PAT of ₹5-6 crores in FY 2026-27 and projects ₹156 crores income with PAT of ₹9-10 crores in FY 2027-28. They are also in discussions for a potential collaboration with a major hotel amenities supplier.

Veerhealth Care Ltd has announced that its Board of Directors will convene on August 13, 2026, at 4:00 PM at its registered office in Mumbai. The primary agenda items include the consideration and approval of the unaudited financial results for the quarter ended June 30, 2026. Additionally, the board will review and approve the draft Director's Report for the financial year ending March 31, 2026, and the draft notice for the 34th Annual General Meeting. The trading window, closed since July 1, 2026, will reopen on August 16, 2026.

Veerhealth Care Ltd has announced the receipt of a significant order from a major FMCG company for the supply of skincare products. The order is valued at ₹526.84 Lakhs and is expected to be executed within 45 days. This new contract represents a substantial growth opportunity for the company, with expectations of increased turnover. The order is for face care products and is from a domestic entity. Veerhealth Care has confirmed that there is no interest from promoters or group companies in the awarding entity, and the transaction does not fall under related party transactions.

Veerhealth Care Ltd has announced a significant export order worth ₹15,73,992 for the supply of Gripe Water from an established buyer in Sudan. This marks the company's entry into the Sudan market and expands its global presence in the pediatric and wellness care segment. The order is to be executed within 45 days. Veerhealth Care aims to leverage this initial order to build long-term relationships and capitalize on opportunities in the African region. The company has confirmed no promoter interest in the awarding entity and that the transaction is not a related party transaction.

Veerhealth Care Limited has announced a new sample order worth approximately ₹76.40 lakhs from a leading Indian FMCG company for its skincare product range. This order is expected to be executed within 45 days and will involve manufacturing products under a new MRP structure for market expansion. The buyer is a prominent business group with a 125-year legacy, operating in the personal and household care segment both domestically and internationally. Veerhealth Care also provided financial projections, expecting total income of ₹105 crores with PAT of ₹5-6 crores in FY 2026-27, and total income of ₹156 crores with PAT of ₹9-10 crores in FY 2027-28. The company highlighted its USFDA plant clearance and ongoing discussions with a major hotel amenities supplier.

Veerhealth Care Limited has announced the receipt of a significant contract manufacturing order valued at ₹76.40 Lakhs for skincare products. The order comes from a leading FMCG company and involves manufacturing products for a new MRP structure aimed at brand promotion and market expansion. The order is to be executed within 45 days. This development signifies a positive business update for the company, highlighting its manufacturing capabilities in the skincare segment and its ability to secure contracts with major players in the FMCG industry. The company has confirmed that the awarding entity is a domestic entity and there is no promoter interest in the awarding entity.

Veerhealth Care Limited has announced a repeat order worth approximately ₹1.11 crores from a leading Indian pharmacy and healthcare company. This order is for the supply of Hair Care and Oral Care Products and is expected to be executed within 45 days. The company, which specializes in Ayurvedic and Herbal Cosmetic products, anticipates this order will contribute to its projected total income of ₹105 crores with a Profit After Tax (PAT) of ₹5-6 crores for FY 2026-27, and ₹156 crores total income with PAT of ₹9-10 crores for FY 2027-28. These projections may be further enhanced by funds raised through a preferential issue of warrants. Veerhealth Care also highlighted its USFDA plant clearance and its specialization in pure vegetarian toothpaste manufacturing.